Sugi Predict

Sugi Predict / Compounds / SCHEMBL1006420

SCHEMBL1006420

SCHEMBL1006420

CCCCC(CCCC[C]=O)NC(=O)[C@@H](CCCNC(=N)N)NC(C)=O

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SIRT6 Q8N6T7 1/20 0.47
▸ SIRT1 Q96EB6 1/20 0.47
▸ SIRT5 Q9NXA8 2/20 0.39
▸ NPY4R P50391 12/20 0.38
▸ NPY1R P25929 7/20 0.38
▸ NPY2R P49146 5/20 0.38
▸ NPY5R Q15761 5/20 0.38
▸ TLR2 O60603 2/20 0.36
▸ DPP7 Q9UHL4 1/20 0.36
▸ MEN1 O00255 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521785 0.86 DPP7 (0.48) NPY4RNPY1RNPY2RNPY5RDPP7
SCHEMBL4284356 0.84 SIRT6 (0.53) SIRT6SIRT1SIRT5NPY4RNPY1R
SCHEMBL31688041 0.79 SIRT6 (0.56) SIRT6SIRT1SIRT5NPY4RNPY1R
SCHEMBL1521788 0.79 SIRT6 (0.48) SIRT6SIRT1SIRT5NPY4RNPY1R
SCHEMBL6935932 0.78 SIRT6 (0.50) SIRT6SIRT1DPP7
SCHEMBL29947289 0.76 KDM4E (0.49) SIRT6SIRT1SIRT5NPY4RNPY1R
SCHEMBL16045801 0.76 SIRT5 (0.57) SIRT6SIRT1SIRT5NPY4RNPY1R
SCHEMBL6940719 0.76 SIRT6 (0.53) SIRT6SIRT1DPP7
SCHEMBL6939793 0.76 SIRT6 (0.53) SIRT6SIRT1DPP7
SCHEMBL15987249 0.76 SIRT5 (0.57) SIRT6SIRT1SIRT5NPY4RNPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212890-A1 METASTIN DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-09-01 — — US claimed
US-20110118172-A1 METASTIN DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-05-19 — — US claimed
EP-2314609-A1 METASTIN DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2011-04-27 — — EP claimed
JP-4653840-B2 — — 2011-03-16 — — JP claimed
US-20110059888-A1 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-03-10 — — US claimed
EP-2277900-A1 METASTIN DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2011-01-26 — — EP claimed
US-20090298765-A1 Metastin derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-03 — — US claimed
EP-2113513-A2 Metastin derivatives and use thereof Takeda Pharmaceutical Company Limited (JP) 2009-11-04 — — EP claimed
US-20090215700-A1 Metastin derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-08-27 — — US claimed
EP-2081955-A1 METASTIN DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2009-07-29 — — EP claimed
JP-2009520682-A — — 2009-05-28 — — JP claimed
US-20090105152-A1 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US claimed
US-20080312155-A1 Metastin Derivatives and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 — — US claimed
EP-1963362-A1 METASTIN DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2008-09-03 — — EP claimed
WO-2008050897-A1 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-02 — — WO claimed
WO-2007072997-A1 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-28 — — WO claimed
EP-1758932-A2 METASTIN DERIVATIVES AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-03-07 — — EP claimed
WO-2006001499-A2 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 — — WO claimed
EP-3210998-A1 METASTIN DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2017-08-30 — — EP disclosed
WO-2006001499-A2 METASTIN DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215700-A1 Metastin derivatives and use thereof SHBG, GNRHR, INHA SIRT6 1725/4885SIRT1 999/4885SIRT5 1876/4885
US-20080312155-A1 Metastin Derivatives and Use Thereof GNRHR, SHBG, MEN1 SIRT6 940/4885SIRT1 480/4885SIRT5 1086/4885
US-20110059888-A1 METASTIN DERIVATIVES AND USE THEREOF SHBG, GNRHR, INHA SIRT6 1725/4885SIRT1 999/4885SIRT5 1876/4885
US-20110118172-A1 METASTIN DERIVATIVE AND USE THEREOF GNRHR, SHBG, INHA SIRT6 1272/4885SIRT1 639/4885SIRT5 1170/4885
US-20090298765-A1 Metastin derivatives and use thereof GNRHR, SHBG, MEN1 SIRT6 940/4885SIRT1 480/4885SIRT5 1086/4885
US-20110212890-A1 METASTIN DERIVATIVE AND USE THEREOF GNRHR, SHBG, LHCGR SIRT6 2375/4885SIRT1 1060/4885SIRT5 2467/4885
US-20090105152-A1 METASTIN DERIVATIVES AND USE THEREOF SHBG, GNRHR, INHA SIRT6 1480/4885SIRT1 890/4885SIRT5 1288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.